摘要
目的比较培美曲塞或紫杉醇联合奈达铂治疗肺腺癌的临床疗效。方法将某三甲医院收治的晚期肺腺癌患者69例随机分为A组(35例)和B组(34例)。A组使用培美曲塞联合奈达铂进行化学治疗(简称化疗),B组使用紫杉醇联合奈达铂进行化疗。结果 A组完全缓解率、部分缓解率及总生存率分别为45.71%,34.29%,80.00%,明显高于B组的26.47%,23.53%,50.00%,A组的进展率明显低于B组;A组和B组出现Ⅰ~Ⅳ级骨髓抑制的比率分别为47.06%和82.86%,差异均有统计学意义(P<0.05),两组其他毒副反应无明显差异。结论培美曲塞联合奈达铂一线治疗肺腺癌的有效率较高,但用于二线治疗时,患者可能会不耐受骨髓抑制等化疗不良反应。
Objective To compare the efficacy of Pemetrexed combined with Nedaplatin and Taxol combined with Nedaplatin in the treatment of lung adenocarcinoma. Methods Totally 69 patients with advanced lung adenocarcinoma admitted to a 3A hospital were randomly divided into group A （35 cases ） and group B （34 cases ） ,the group A was given Pemetrexed combined with Nedaplatin for chemotherapy,while the group B was given Taxol combined with Nedaplatin for chemotherapy. Results The complete remission rate, partial remission rate and overall survival rate in the A group were 45. 71%,34. 29% and 80. 00%,which were obviously higher than 26. 47%,23. 53% and 50. 00% in the group B,the rate of progression in the group A was significantly lower than that in the group B. The incidence rate of Ⅰ-Ⅳ grade myelosuppression in the group A and the group B was 47. 06% and 82. 86%,respectively,all the differences were statistically significant （P 〈 0. 05 ） . There was no significant difference in other toxic reactions between the two groups. Conclusion Pemetrexed combined with nedaplatin in first-line treatment of lung adenocarcinoma has better efficacy,but the patients can′t resist to the chemotherapy adverse reactions such as myelosuppression in the second-line treatment.
作者
周英文
周玉福
张莉梅
Zhou Yingwen Zhou Yufu Zhang Limei(Maternal and Child Health Care Hospital of Beibei District, Chongqing, China 40070)
出处
《中国药业》
CAS
2017年第12期53-55,共3页
China Pharmaceuticals
关键词
培美曲塞
紫杉醇
奈达铂
肺腺癌
一线治疗
Pemetrexed
Taxol
Nedaplatin
lung adenocarcinoma
first-line treatment
